S&P 500   3,818.83
DOW   31,029.31
QQQ   283.80
S&P 500   3,818.83
DOW   31,029.31
QQQ   283.80
S&P 500   3,818.83
DOW   31,029.31
QQQ   283.80
S&P 500   3,818.83
DOW   31,029.31
QQQ   283.80

PhaseBio Pharmaceuticals Stock Forecast, Price & News

+0.01 (+1.54%)
(As of 06/29/2022 12:00 AM ET)
Today's Range
50-Day Range
52-Week Range
220,002 shs
Average Volume
566,484 shs
Market Capitalization
$32.00 million
P/E Ratio
Dividend Yield
Price Target
30 days | 90 days | 365 days | Advanced Chart

Receive PHAS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for PhaseBio Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

PHAS Stock Forecast (MarketRank)

Overall MarketRank

2.01 out of 5 stars

Medical Sector

595th out of 1,432 stocks

Pharmaceutical Preparations Industry

271st out of 685 stocks

Analyst Opinion: 3.5Community Rank: 4.3Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.6 5 -4 -3 -2 -1 -
PhaseBio Pharmaceuticals logo

About PhaseBio Pharmaceuticals (NASDAQ:PHAS)

PhaseBio Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel for cardiovascular diseases. Its lead product candidate is bentracimab (PB2452), a reversal agent for the antiplatelet drug ticagrelor that is in Phase III clinical trial for patients with uncontrolled major or life-threatening bleeding events or in patients requiring urgent or an invasive procedure. The company is also developing PB1046, a vasoactive intestinal peptide analogue for the treatment of pulmonary arterial hypertension; and PB6440 for the treatment of resistant hypertension. The company has a co-development agreement with SFJ Pharmaceuticals X, Ltd. to develop PB2452, a reversal agent for the antiplatelet drug ticagrelor. PhaseBio Pharmaceuticals, Inc. was incorporated in 2002 and is based in Malvern, Pennsylvania.

PHAS Stock News Headlines

See More Headlines

Industry, Sector and Symbol

Pharmaceutical preparations
Current Symbol
Year Founded

Company Calendar

Last Earnings
Next Earnings (Estimated)
Fiscal Year End

Price Target and Rating

Average Stock Price Forecast
High Stock Price Forecast
Low Stock Price Forecast
Forecasted Upside/Downside
Consensus Rating
Rating Score (0-4)
Research Coverage
3 Analysts


Net Income
$-131.07 million
Net Margins
Pretax Margin


Sales & Book Value

Annual Sales
$10.83 million
Book Value
($1.93) per share


Free Float
Market Cap
$32.00 million
Not Optionable

PhaseBio Pharmaceuticals Frequently Asked Questions

Should I buy or sell PhaseBio Pharmaceuticals stock right now?

3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for PhaseBio Pharmaceuticals in the last year. There are currently 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" PhaseBio Pharmaceuticals stock.
View analyst ratings for PhaseBio Pharmaceuticals
or view top-rated stocks.

What is PhaseBio Pharmaceuticals' stock price forecast for 2022?

3 Wall Street analysts have issued 12-month price objectives for PhaseBio Pharmaceuticals' stock. Their PHAS stock forecasts range from $10.00 to $15.00. On average, they predict PhaseBio Pharmaceuticals' share price to reach $12.50 in the next year. This suggests a possible upside of 1,801.7% from the stock's current price.
View analysts' price targets for PhaseBio Pharmaceuticals
or view top-rated stocks among Wall Street analysts.

How has PhaseBio Pharmaceuticals' stock performed in 2022?

PhaseBio Pharmaceuticals' stock was trading at $2.61 at the start of the year. Since then, PHAS shares have decreased by 74.8% and is now trading at $0.6573.
View the best growth stocks for 2022 here

When is PhaseBio Pharmaceuticals' next earnings date?

PhaseBio Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Thursday, August 11th 2022.
View our earnings forecast for PhaseBio Pharmaceuticals

How were PhaseBio Pharmaceuticals' earnings last quarter?

PhaseBio Pharmaceuticals, Inc. (NASDAQ:PHAS) announced its quarterly earnings data on Monday, May, 16th. The company reported ($0.23) earnings per share for the quarter, beating analysts' consensus estimates of ($0.67) by $0.44. The firm had revenue of $0.12 million for the quarter, compared to the consensus estimate of $5.83 million.
View PhaseBio Pharmaceuticals' earnings history

Who are PhaseBio Pharmaceuticals' key executives?

PhaseBio Pharmaceuticals' management team includes the following people:
  • Mr. Jonathan P. Mow MBA, Pres, CEO & Director (Age 57, Pay $894.66k)
  • Mr. John P. Sharp CPA, Chief Financial Officer (Age 57, Pay $573.34k)
  • Dr. John S. Lee M.D., Ph.D., Chief Medical Officer (Age 54, Pay $648.88k)
  • Ms. Susan Elizabeth Arnold Ph.D., Sr. VP of Technical Operations (Age 47)
  • Mr. Kristopher L. Hanson, SVP, Gen. Counsel & Corp. Sec. (Age 50)
  • Mr. Glen G. Burkhardt, Sr. VP of HR (Age 63) (LinkedIn Profile)
  • Ms. Lauren Richardson, Global Head of Regulatory Affairs & Quality Assurance
  • Mr. Jonathan J. Birchall, Chief Commercial Officer (Age 53)

What other stocks do shareholders of PhaseBio Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other PhaseBio Pharmaceuticals investors own include Axsome Therapeutics (AXSM), Dynavax Technologies (DVAX), SCYNEXIS (SCYX), VBI Vaccines (VBIV), Viking Therapeutics (VKTX), Selecta Biosciences (SELB), Sorrento Therapeutics (SRNE), Amarin (AMRN), Vaxart (VXRT) and Agile Therapeutics (AGRX).

When did PhaseBio Pharmaceuticals IPO?

(PHAS) raised $66 million in an initial public offering (IPO) on Thursday, October 18th 2018. The company issued 5,000,000 shares at $12.50-$14.00 per share. Citigroup, Cowen and Stifel acted as the underwriters for the IPO and Needham was co-manager.

What is PhaseBio Pharmaceuticals' stock symbol?

PhaseBio Pharmaceuticals trades on the NASDAQ under the ticker symbol "PHAS."

How do I buy shares of PhaseBio Pharmaceuticals?

Shares of PHAS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is PhaseBio Pharmaceuticals' stock price today?

One share of PHAS stock can currently be purchased for approximately $0.66.

How much money does PhaseBio Pharmaceuticals make?

PhaseBio Pharmaceuticals (NASDAQ:PHAS) has a market capitalization of $32.00 million and generates $10.83 million in revenue each year. The company earns $-131.07 million in net income (profit) each year or ($2.39) on an earnings per share basis.

How many employees does PhaseBio Pharmaceuticals have?

PhaseBio Pharmaceuticals employs 60 workers across the globe.

How can I contact PhaseBio Pharmaceuticals?

PhaseBio Pharmaceuticals' mailing address is 1 Great Valley Parkway Suite 30, Malvern PA, 19355. The official website for PhaseBio Pharmaceuticals is www.phasebio.com. The company can be reached via phone at (610) 981-6500 or via email at [email protected].

This page (NASDAQ:PHAS) was last updated on 6/30/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer.